Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.

@article{Tang2015TargetingTV,
  title={Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.},
  author={Li Tang and Rong Tong and Virginia J Coyle and Qian Yin and Holly C. Pondenis and Luke B. Borst and Jianjun Cheng and Timothy M Fan},
  journal={ACS nano},
  year={2015},
  volume={9 5},
  pages={
          5072-81
        }
}
An A10 aptamer (Apt)-functionalized, sub-100 nm doxorubicin-polylactide (Doxo-PLA) nanoconjugate (NC) with controlled release profile was developed as an intravenous therapeutic strategy to effectively target and cytoreduce canine hemangiosarcoma (cHSA), a naturally occurring solid tumor malignancy composed solely of tumor-associated endothelium. cHSA consists of a pure population of malignant endothelial cells expressing prostate-specific membrane antigen (PSMA) and is an ideal comparative… CONTINUE READING